Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

testius Nov. 8 at 4:12 AM

$IFRX Biogen $BIIB is still hunting for "a couple more" C5a companies "by end of the year". Their last licensing, from Vanqua, an early stage company - earlier than Inflarx - valued total payments of 1 billion. A market cap of 1 billion means for Inflarx some 15 USD per share.

1 · Reply

testius Nov. 8 at 4:12 AM

$IFRXBIOGEN $BIIB is still hunting for "a couple more" C5a companies "by end of the year". Their last licensing, from Vanqua, an early stage company - earlier than Inflarx - valued total payments of 1 billion. A market cap of 1 billion means for Inflarx some 15 USD per share.

0 · Reply

testius Nov. 8 at 4:06 AM

$IFRXBIOGEN $BIIB is hunting for "a couple more" C5a companies by end of year. Their last licensing from Vanqua, an early stage company, earlier than Inflarx, valued payments in total of 1 billion. A 1 billion market cap means for Inflarx about 15 USD per share.

0 · Reply

RunnerSignals Nov. 7 at 8:48 PM

Analysts Go Bullish on $BIDU $VOD $LAC $BIIB $U Wall Street's changing its tune on these names. Read the full breakdown 👇 https://stocksrunner.com/news/2025-11-07-stock-upgrades-today-wall-street-analysts-signal-strong-buys

0 · Reply

OfficialStocktwitsUser Nov. 7 at 2:36 PM

$BIIB RSI: 71.04, MACD: 1.9374 Vol: 3.34, MA20: 148.09, MA50: 145.20 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

RunnerSignals Nov. 7 at 5:41 AM

Fresh upgrades dropping! $BIIB $CRL $JKHY $RBC $SMCI check the story here... https://stocksrunner.com/news/2025-11-06-fresh-stock-upgrades

0 · Reply

isabellacollins77 Nov. 6 at 8:54 PM

$BIIB big biotech, pipeline catalysts. $240 reclaim opens $248–252. Slow but powerful moves. Let it base.

0 · Reply

dogDazeSummer Nov. 6 at 5:42 PM

$IFRX Japanese study Gil was referencing that’s concerning $AMGN around avacopan. And influencing $BIIB to purchase PMX205 The 2nd generation orals INF904 and PMX205 don’t have the safety issues: https://ard.eular.org/article/S0003-4967(25)04113-5/abstract

0 · Reply

dogDazeSummer Nov. 6 at 2:16 PM

$MLTX rejected $MRK offer at $60 months back yet raised $75M today at $10.50 w 7m newly issued shares. Pride, Ego, Greed and bias can get the best of us - but learn from other failures. Their drug had a high placed effect seen over and over in immuno-derm. Osonelokimab's safety is decent in HS, but tied to IL-17 class risks, while INF904's selectivity could make it preferable if Phase 2 data confirm low AE rates. For HS, treatment choice will depend on individual factors (infection history) and $IFRX pending data - but the differentiated MOA is much needed. Who else want to join part now that Moonlake is in “crescent status”? $BIIB $PFE

2 · Reply

topstockalerts Nov. 6 at 1:44 PM

Stifel upgraded Biogen from Hold to Buy in a Thursday note, raising its price target to $202 from $144, citing an improving risk/reward profile for the stock due to multiple clinical catalysts and a potential "narrative shift" in Alzheimer's disease. "This is not a recommendation based on the core business," wrote analyst Paul Matteis, noting that Biogen's third-quarter results were mixed, and the firm expects the fourth quarter to be "barely acceptable." Instead, Stifel sees upside potential over the next 12 months driven by developments in Biogen's Alzheimer’s pipeline and beyond. According to Stifel, Biogen’s shares could benefit from "the potential success of LLY’s TB3 trial, which could fundamentally change how patients, doctors, and investors think about abeta antibodies," as well as the "likely approval for the initiation of lecanemab SQ," which could alleviate current treatment bottlenecks. $LLY $IONS $BIIB

0 · Reply

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Oct 30, 2025, 9:16 PM EDT - 8 days ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:40 AM EDT - 8 days ago

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Oct 30, 2025, 6:11 AM EDT - 9 days ago

Biogen trims annual profit forecast on expected hit from R&D-related charges

Oct 26, 2025, 7:30 PM EDT - 12 days ago

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease

Oct 24, 2025, 8:30 AM EDT - 14 days ago

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion

Oct 24, 2025, 7:30 AM EDT - 14 days ago

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Oct 22, 2025, 7:30 AM EDT - 16 days ago

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Oct 13, 2025, 7:30 PM EDT - 25 days ago

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

Oct 9, 2025, 4:30 PM EDT - 4 weeks ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Oct 9, 2025, 4:30 PM EDT - 4 weeks ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

STOK

Oct 9, 2025, 10:54 AM EDT - 4 weeks ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 6, 2025, 4:30 PM EDT - 4 weeks ago

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

Oct 6, 2025, 1:29 PM EDT - 4 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BMY GILD

Oct 3, 2025, 8:50 AM EDT - 5 weeks ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 1, 2025, 5:48 PM EDT - 5 weeks ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BMY IBB LLY MRK MRNA PFE

Sep 28, 2025, 7:30 PM EDT - 5 weeks ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

Sep 26, 2025, 12:21 PM EDT - 6 weeks ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

ABBV LLY MRK PFE BMY

Sep 24, 2025, 2:17 PM EDT - 6 weeks ago

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 7:30 AM EDT - 6 weeks ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia

Sep 23, 2025, 4:41 PM EDT - 6 weeks ago

US FDA declines to approve higher-dose of Biogen's genetic disorder drug

Sep 23, 2025, 4:30 PM EDT - 6 weeks ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

Sep 18, 2025, 7:40 AM EDT - 7 weeks ago

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Sep 17, 2025, 4:30 PM EDT - 7 weeks ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Sep 8, 2025, 6:51 PM EDT - 2 months ago

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 2:09 PM EDT - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD JNJ LLY MRK

Sep 2, 2025, 7:30 PM EDT - 2 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

STOK

Sep 2, 2025, 4:54 AM EDT - 2 months ago

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

NIO NVDA

Aug 29, 2025, 5:08 PM EDT - 2 months ago

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

Aug 29, 2025, 5:00 PM EDT - 2 months ago

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Aug 28, 2025, 2:16 PM EDT - 2 months ago

FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

STOK

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Aug 25, 2025, 3:00 AM EDT - 2 months ago

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

Aug 11, 2025, 7:00 AM EDT - 3 months ago

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Aug 11, 2025, 7:00 AM EDT - 3 months ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

STOK

Aug 2, 2025, 9:15 AM EDT - 3 months ago

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 2:24 PM EDT - 3 months ago

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:17 AM EDT - 3 months ago

Biogen raises annual profit forecast on strong demand for rare disease drugs

Jul 30, 2025, 11:00 AM EDT - 3 months ago

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Jul 30, 2025, 8:12 AM EDT - 3 months ago

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Jul 25, 2025, 7:20 AM EDT - 3 months ago

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Jul 21, 2025, 7:30 PM EDT - 3 months ago

Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025

Jul 21, 2025, 2:25 PM EDT - 3 months ago

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Jul 21, 2025, 7:41 AM EDT - 3 months ago

Biogen to invest $2 billion more in North Carolina

testius Nov. 8 at 4:12 AM

1 · Reply

testius Nov. 8 at 4:12 AM

0 · Reply

testius Nov. 8 at 4:06 AM

0 · Reply

RunnerSignals Nov. 7 at 8:48 PM

0 · Reply

OfficialStocktwitsUser Nov. 7 at 2:36 PM

0 · Reply

RunnerSignals Nov. 7 at 5:41 AM

Fresh upgrades dropping! $BIIB $CRL $JKHY $RBC $SMCI check the story here... https://stocksrunner.com/news/2025-11-06-fresh-stock-upgrades

0 · Reply

isabellacollins77 Nov. 6 at 8:54 PM

$BIIB big biotech, pipeline catalysts. $240 reclaim opens $248–252. Slow but powerful moves. Let it base.

0 · Reply

dogDazeSummer Nov. 6 at 5:42 PM

0 · Reply

dogDazeSummer Nov. 6 at 2:16 PM

2 · Reply

topstockalerts Nov. 6 at 1:44 PM

0 · Reply

JarvisFlow Nov. 6 at 12:46 PM

Stifel has updated their rating for Biogen ( $BIIB ) to Buy with a price target of 202.

0 · Reply

Chartist0_0 Nov. 6 at 11:41 AM

$BIIB I see this as one of the best opportunities in the space. From a chart perspective, I think 225$ is possible by the end of March.

0 · Reply

theflynews Nov. 6 at 10:18 AM

Biogen just upgraded at Stifel, here's why - $BIIB - https://thefly.com/permalinks/entry.php/BIIBid4232038?1762424227C38

0 · Reply

dogDazeSummer Nov. 5 at 10:15 PM

$IFRX $AMGN $BIIB $ABBV $RHHBY

0 · Reply

dogDazeSummer Nov. 4 at 2:13 PM

$AMGN $IFRX $BIIB This is Amgens funded research - what does it signify by funding this study? No need for the most commonly prescribed item—-> steroids? Follow the money / follow the studies. https://ancavasculitisnews.com/news/tavneos-combo-similarly-effective-corticosteroids-aav-remission-trial/

0 · Reply

dogDazeSummer Nov. 4 at 2:09 PM

https://pubmed.ncbi.nlm.nih.gov/41151615/ Out today … “The C5a receptor blocker avacopan allows significant reduction of the cumulative glucocorticoids during AAV induction treatment, while increasing sustained remission and improving the glomerular filtration rate. Therefore, avacopan is now considered in the guideline as an alternative to glucocorticoids.” $AMGN $BIIB $IFRX and Staidson all seems to understand the axis. Wonder if anyone else will in coming months?

1 · Reply

OfficialStocktwitsUser Nov. 4 at 12:34 PM

$BIIB RSI: 62.65, MACD: 1.8483 Vol: 3.24, MA20: 148.08, MA50: 144.60 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JarvisFlow Nov. 3 at 12:49 PM

Bernstein has adjusted their stance on Biogen ( $BIIB ), setting the rating to Market Perform with a target price of 155 → 157.

0 · Reply

Albino_Trader123 Nov. 3 at 4:57 AM

$BIIB If you are long term investment holder. This is a bargain here. Gap down after ER, bought up like mofo. Lots of approved drugs, super undervalued. No brainer for a long term investment

0 · Reply

dogDazeSummer Nov. 1 at 10:21 PM

$IFRX @MrCompassion Also on Page 64 of annual report - note the mechanism is explained so even a caveman can understand😀 Hopefully helps explain the C5a is what invites many IL blockers. See quote from Inflarx annual report. Explains upstream/ downstream —- “In the inflammatory response, C5a is an accelerator or “booster” of inflammation. This role of CSa extends to a broad variety of responses including the following mechanisms: *****C5a booths the generation of many different cytokines such as IL-8, IL-6, L17, TINF-alpha and others in a variety of cell types as well as within the bloodstream”****** 2 of the biggest names in biotech get c5a axis is indeed a pipeline. $AMGN $BIIB 40 minutes into Biogen call Thursday, here was answer Q&A: 0:40:01 And Vanqua is just one example of bringing in an asset that could actually have multiple indications. And I think you'll see us do more of those…… in diseases, NRF2, microglia, things like that that actually cross over diseases.”

0 · Reply

dogDazeSummer Oct. 31 at 9:51 PM

$PFE $MTSR $NVO well that escalated quickly How bout one of u guys follow $BIIB and drop $4-$5B on C5aR antagonist Inflarx ? $IFRX Go—-hibic! #INF904

2 · Reply

dogDazeSummer Oct. 31 at 12:07 PM

aggregated notes $BIIB call relvevant to $AMGN $IFRX #KWYO 0:12:11 “One of the reasons that we're doing these early stage deals is I think we now need to build an early stage pipeline, and Vanqua is just one example of that.” Speaker 8 0:38:10 “I argued that we've always been in immunology because basically a lot of diseases like MS, we are treating by really trying to have an impact on the immune system. You know, as I pointed out, you know, our MS drugs don't even cross the blood brain barrier, so I would argue we've always been an immunology company. And immunology is really an area that has really flourished over the last ten years, and I think DUPIXENT was really one of the first drugs to really demonstrate..” Speaker 2 0:40:01 And Vanqua is just one example of bringing in an asset that could actually have multiple indications. And I think you'll see us do more of those…… in diseases, NRF2, microglia, things like that that actually cross over diseases.”

1 · Reply

Market Cap	22.99B
Revenue (ttm)	9.68B
Net Income (ttm)	1.63B
EPS (ttm)	N/A
PE Ratio	9.17
Forward PE	10.32
Profit Margin	16.87%
Debt to Equity Ratio	0.35

Volume	1,526,200
Avg Vol	1,725,148
Day's Range	N/A - N/A
Shares Out	146.70M
Stochastic %K	88%
Beta	0.10
Analysts	Sell
Price Target	$173.93